Archival of Human Biological Samples in CU-Med Biobank

February 9, 2024 updated by: Professor Ronald C.W. Ma, Chinese University of Hong Kong
CU-Med Biobank collaborates with different researchers for collecting and distributing human biospecimens and clinical data for assisting scientific research.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

CU-Med Biobank will collect and store high-quality specimens from cancer-related or other diseases. All samples are linked to annotated clinical data from approved consented protocols. This system provides researchers with high- quality biological samples and comprehensive clinical, pathological including molecular/genetic information for their research. This standardized CU-Med Biobank is a pivotal bridge to improve the translation of basic research into clinical applications. These findings will contribute to improve prevention, enhance diagnosis, develop new treatment and eventual cure of diseases.

Study Type

Observational

Enrollment (Estimated)

10000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

The diverse group of biorepositories with focus on normal cohorts and cancer-related or other disease cohorts.

Description

Inclusion Criteria:

  • Enrolled subjects that have provided signed consent for the specimens and de-identified data to be collected, stored and distributed.

Exclusion Criteria:

  • Subjects without signed informed consent for the specimens and de-identified data to be collected, stored and distributed.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Healthy Control
Healthy subjects who have provided consent for specimen collection
Procedure: Specimen Collection
Specimens obtained from surgical, phlebotomy or other non-invasive procedure
Cancer or Other Diseases
Diseased subjects who have provided consent for specimen collection
Procedure: Specimen Collection
Specimens obtained from surgical, phlebotomy or other non-invasive procedure

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To distribute human biospecimens for clinical research
Time Frame: 99 years
By using the biological samples from CU-Med Biobank, translational studies can be done.
99 years
To discover the pathological mechanism of different acute and chronic diseases such as cancer, stroke, heart disease, dementia & diabetes
Time Frame: 99 years
The relationship between different genome/proteome/bacteriome/virome and various diseases can be revealed, thus leading to a better prognostic and diagnostic outcome.
99 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Chinese University of Hong Kong

Investigators

  • Study Chair: Ching Wan MA, MB BChir, Chinese University of Hong Kong

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2020

Primary Completion (Estimated)

December 1, 2050

Study Completion (Estimated)

December 1, 2050

Study Registration Dates

First Submitted

December 28, 2020

First Submitted That Met QC Criteria

January 11, 2021

First Posted (Actual)

January 12, 2021

Study Record Updates

Last Update Posted (Actual)

February 12, 2024

Last Update Submitted That Met QC Criteria

February 9, 2024

Last Verified

February 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CREC 2019.152

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Heart Diseases

Clinical Trials on Specimen Collection

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burundi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe